Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,441 to 4,460 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| HZ/su Group vs Placebo Group: Number of Participants With SAEs Related to Investigational Vaccine, Related to Study Participation or to GSK Concomitant Medication/Vaccine | 1 of 714 1 of 712 | -0.0 points -0.7 to 0.7 | 1,426 | NCT04091451 Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster |
| HZ/su Group vs Placebo Group: deaths from any cause | 12 of 714 8 of 712 | 0.6 points -0.7 to 1.9 | 1,426 | NCT04091451 Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster |
| HZ/su Group vs Placebo Group: serious adverse events | 56 of 714 43 of 712 | 1.8 points -0.9 to 4.5 | 1,426 | NCT04091451 Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster |
| Restrictive vs Liberal: serious adverse events | 386 of 712 372 of 712 | 2.0 points -3.2 to 7.1 | 1,424 | NCT03229941 Transfusion Trigger After Operations in High Cardiac Risk Patients |
| Intervention vs Control: Facility-level Inappropriate Prostate Cancer Bone Scan Imaging Rates | 109 of 734 141 of 690 | -5.6 points -9.6 to -1.6 | 1,424 | NCT03445559 A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging |
| STS101 5.2 mg vs STS101 Placebo: Percentage of Subjects With Freedom From Most-Bothersome Symptom at 2 Hours Post Dose | 265 of 716 230 of 708 | 4.5 points -0.4 to 9.4 | 1,424 | NCT04940390 A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine |
| STS101 5.2 mg vs STS101 Placebo: Percentage of Subjects With Freedom From Migraine Headache Pain at 2 Hours Post Dose | 146 of 716 124 of 708 | 2.9 points -1.2 to 6.9 | 1,424 | NCT04940390 A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine |
| STS101 5.2 mg vs STS101 Placebo: Percentage of Subjects With Relief From Migraine Headache Pain at 2 Hours Post Dose | 379 of 716 316 of 708 | 8.3 points 3.1 to 13.4 | 1,424 | NCT04940390 A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine |
| Candesartan vs Placebo: Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale. | 178 of 711 217 of 710 | -5.5 points -10.2 to -0.9 | 1,421 | NCT00252733 Diabetic Retinopathy Candesartan Trials |
| Oracea® as Monotherapy vs Oracea® as add-on Therapy: Number of Treatment Responders at Endpoint, Where Response is Defined as an IGA Score of 0 (Clear) or 1 (Near Clear) | 616 of 1,197 106 of 224 | 4.1 points -3.0 to 11.2 | 1,421 | NCT00892281 ORCA - Oracea® for Rosacea: A Community-based Assessment |
| Dabigatran (Dabigatran vs VKA) vs Vitamin K Antagonists (VKA): deaths from any cause | 10 of 771 5 of 650 | 0.5 points -0.6 to 1.7 | 1,421 | NCT02240667 Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF) |
| Dabigatran (Dabigatran vs VKA) vs Vitamin K Antagonists (VKA): serious adverse events | 45 of 771 39 of 650 | -0.2 points -2.7 to 2.3 | 1,421 | NCT02240667 Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF) |
| Candesartan vs Placebo: serious adverse events | 102 of 710 112 of 710 | -1.4 points -5.1 to 2.3 | 1,420 | NCT00252733 Diabetic Retinopathy Candesartan Trials |
| Oracea® as Monotherapy vs Oracea® as add-on Therapy: serious adverse events | 5 of 1,196 0 of 224 | 0.4 points -1.3 to 1.0 | 1,420 | NCT00892281 ORCA - Oracea® for Rosacea: A Community-based Assessment |
| Video Laryngoscope Group vs Direct Laryngoscope Group: Operator-reported Aspiration | 7 of 705 12 of 712 | -0.7 points -2.0 to 0.6 | 1,417 | NCT05239195 DirEct Versus VIdeo LaryngosCopE Trial |
| Video Laryngoscope Group vs Direct Laryngoscope Group: Number of Participants With Severe Complications of Tracheal Intubation | 151 of 705 149 of 712 | 0.5 points -3.8 to 4.7 | 1,417 | NCT05239195 DirEct Versus VIdeo LaryngosCopE Trial |
| Video Laryngoscope Group vs Direct Laryngoscope Group: All-cause In-hospital Mortality | 184 of 705 191 of 712 | -0.7 points -5.3 to 3.9 | 1,417 | NCT05239195 DirEct Versus VIdeo LaryngosCopE Trial |
| Video Laryngoscope Group vs Direct Laryngoscope Group: Injury to the Teeth | 3 of 705 2 of 712 | 0.1 points -0.6 to 1.0 | 1,417 | NCT05239195 DirEct Versus VIdeo LaryngosCopE Trial |
| Video Laryngoscope Group vs Direct Laryngoscope Group: Number of Intubations With Successful Intubation on the First Attempt | 600 of 705 504 of 712 | 14.3 points 10.0 to 18.5 | 1,417 | NCT05239195 DirEct Versus VIdeo LaryngosCopE Trial |
| Video Laryngoscope Group vs Direct Laryngoscope Group: Successful Intubation on the First Attempt Without a Severe Complication | 484 of 705 420 of 712 | 9.7 points 4.7 to 14.6 | 1,417 | NCT05239195 DirEct Versus VIdeo LaryngosCopE Trial |
Code
curl "https://conductscience.org/api/comparisons/v1?page=223"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=223
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT04091451-9af7180d",
"title": "HZ/su Group vs Placebo Group: Number of Participants With SAEs Related to Investigational Vaccine, Related to Study Participation or to GSK Concomitant Medication/Vaccine",
"summary": "1 of 714 against 1 of 712; risk difference -0.0 points, 95% interval -0.7 to 0.7; NCT04091451, Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster",
"record": "/library/comparisons/NCT04091451-9af7180d",
"nct_id": "NCT04091451",
"kind": "outcome",
"participants": 1426,
"risk_difference": {
"value": -0.000003934157932836005,
"lower": -0.0066131379131841575,
"upper": 0.006588009024119329
},
"group_1": "1 of 714",
"group_2": "1 of 712",
"difference": "-0.0 points",
"interval": "-0.7 to 0.7",
"trial_title": "Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster"
},
{
"id": "NCT04091451-deaths",
"title": "HZ/su Group vs Placebo Group: deaths from any cause",
"summary": "12 of 714 against 8 of 712; risk difference 0.6 points, 95% interval -0.7 to 1.9; NCT04091451, Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster",
"record": "/library/comparisons/NCT04091451-deaths",
"nct_id": "NCT04091451",
"kind": "deaths",
"participants": 1426,
"risk_difference": {
"value": 0.0055707676328958546,
"lower": -0.007372152170508749,
"upper": 0.019092478805890496
},
"group_1": "12 of 714",
"group_2": "8 of 712",
"difference": "0.6 points",
"interval": "-0.7 to 1.9",
"trial_title": "Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=224",
"request_id": "XLSY4618YQai9MgA"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant